This Week in Biotech: Part 2
With 11 noteworthy biotech events this week, Part 2 of this weekly series looks at six clinical updates that amazed investors, including a mid-stage cancer trial that sent shares of one company up 74% while a large pharmaceutical company chalked up another failure.
High-Risk Pipeline Candidates and Limited Options Make Novartis an Iffy Buy Candidate
With a lot of attention on high-risk programs and unlikely strategic moves, Novartis may struggle to outperform from these levels.
Zoetis Stock: 3 Key Investing Lessons from 2013
Will new developments from Novartis, Merck, and Eli Lilly threaten Zoetis’ dominance of the animal health business? What 3 key lessons should investors learn from Zoetis’ performance throughout 2013 since it was spun off from Pfizer?
Mylan Nabs India, Roche Takes Europe in Breast Cancer Therapies
Mylan and Biocon gain approval for Herceptin biosimilar in India while Roche and ImmunoGen gain approval for Herceptin-DM1 combination Kadcyla in Europe.